Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
- Autores
- de Kantor, Isabel N.; Barrera, Lucía
- Año de publicación
- 2007
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina.
Fil: Barrera, Lucia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
The value of susceptibility tests in guiding antituberculous therapy with second-line drugs remains controversial. We reanalyzed three reports regarding the relationship between in vitro susceptibility of Mycobacterium tuberculosis and the clinical outcome of in-patients treated with these drugs at the Muñiz Hospital, Buenos Aires, during the sixties. These patients had been irregularly treated with a standard regimen consisting of isoniazid, streptomycin and PAS; they developed resistance to at least the first two drugs and persisted culture-positive. Susceptibility testing to ethionamide, cycloserine and kanamycin were performed by the proportion method on Löwenstein Jensen medium. Some level of resistance was detected among isolates from patients not previously treated with these drugs, that could be due to cross resistance with previously administered first line structural analogs. However, the studies evidenced significant association between resistance to ethionamide and cycloserine and prior treatment with these drugs. Increased resistance to all three drugs was detected within the first three months of treatment. In vitro resistance to ethionamide emerged earlier and was the most frequent followed by resistance to cycloserine and kanamycin. The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time. Simultaneous resistance to the three agents, but not to two or one drug, appeared to be a marker of treatment failure. An apparent reversion of drug resistance was observed in near 6% of patients, for whom susceptibility tests were repeated on subsequent isolates, indicating this percentage of inconsistency in reproducibility of test results. - Fuente
- Medicina (Buenos Aires) 2007; 67(3): 231-237.
- Materia
-
Tuberculosis
Tuberculosis Pulmonar
Mycobacterium tuberculosis
Tuberculosis Resistente a Múltiples Medicamentos
Argentina - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- Repositorio
- Institución
- Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
- OAI Identificador
- oai:sgc.anlis.gob.ar:123456789/144
Ver los metadatos del registro completo
id |
SGCANLIS_f8428c312deccf2fdce4df59d43c9830 |
---|---|
oai_identifier_str |
oai:sgc.anlis.gob.ar:123456789/144 |
network_acronym_str |
SGCANLIS |
repository_id_str |
a |
network_name_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
spelling |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiencesLas pruebas de sensibilidad a drogas de segunda línea y el re-tratamiento de la tuberculosis: visión retrospectiva de tres estudiosde Kantor, Isabel N.Barrera, LucíaTuberculosisTuberculosis PulmonarMycobacterium tuberculosisTuberculosis Resistente a Múltiples MedicamentosArgentinaFil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina.Fil: Barrera, Lucia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.The value of susceptibility tests in guiding antituberculous therapy with second-line drugs remains controversial. We reanalyzed three reports regarding the relationship between in vitro susceptibility of Mycobacterium tuberculosis and the clinical outcome of in-patients treated with these drugs at the Muñiz Hospital, Buenos Aires, during the sixties. These patients had been irregularly treated with a standard regimen consisting of isoniazid, streptomycin and PAS; they developed resistance to at least the first two drugs and persisted culture-positive. Susceptibility testing to ethionamide, cycloserine and kanamycin were performed by the proportion method on Löwenstein Jensen medium. Some level of resistance was detected among isolates from patients not previously treated with these drugs, that could be due to cross resistance with previously administered first line structural analogs. However, the studies evidenced significant association between resistance to ethionamide and cycloserine and prior treatment with these drugs. Increased resistance to all three drugs was detected within the first three months of treatment. In vitro resistance to ethionamide emerged earlier and was the most frequent followed by resistance to cycloserine and kanamycin. The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time. Simultaneous resistance to the three agents, but not to two or one drug, appeared to be a marker of treatment failure. An apparent reversion of drug resistance was observed in near 6% of patients, for whom susceptibility tests were repeated on subsequent isolates, indicating this percentage of inconsistency in reproducibility of test results.2007info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf0025-7680http://sgc.anlis.gob.ar/handle/123456789/144http://www.medicinabuenosaires.com/revistas/vol67-07/3/completo/v67_3_p231_237.pdfMedicina (Buenos Aires) 2007; 67(3): 231-237.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISMedicina (Buenos Aires)ARGenginfo:eu-repo/semantics/openAccess2025-09-04T11:15:12Zoai:sgc.anlis.gob.ar:123456789/144Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-04 11:15:12.496Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false |
dc.title.none.fl_str_mv |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences Las pruebas de sensibilidad a drogas de segunda línea y el re-tratamiento de la tuberculosis: visión retrospectiva de tres estudios |
title |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences |
spellingShingle |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences de Kantor, Isabel N. Tuberculosis Tuberculosis Pulmonar Mycobacterium tuberculosis Tuberculosis Resistente a Múltiples Medicamentos Argentina |
title_short |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences |
title_full |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences |
title_fullStr |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences |
title_full_unstemmed |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences |
title_sort |
Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences |
dc.creator.none.fl_str_mv |
de Kantor, Isabel N. Barrera, Lucía |
author |
de Kantor, Isabel N. |
author_facet |
de Kantor, Isabel N. Barrera, Lucía |
author_role |
author |
author2 |
Barrera, Lucía |
author2_role |
author |
dc.subject.none.fl_str_mv |
Tuberculosis Tuberculosis Pulmonar Mycobacterium tuberculosis Tuberculosis Resistente a Múltiples Medicamentos Argentina |
topic |
Tuberculosis Tuberculosis Pulmonar Mycobacterium tuberculosis Tuberculosis Resistente a Múltiples Medicamentos Argentina |
dc.description.none.fl_txt_mv |
Fil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina. Fil: Barrera, Lucia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. The value of susceptibility tests in guiding antituberculous therapy with second-line drugs remains controversial. We reanalyzed three reports regarding the relationship between in vitro susceptibility of Mycobacterium tuberculosis and the clinical outcome of in-patients treated with these drugs at the Muñiz Hospital, Buenos Aires, during the sixties. These patients had been irregularly treated with a standard regimen consisting of isoniazid, streptomycin and PAS; they developed resistance to at least the first two drugs and persisted culture-positive. Susceptibility testing to ethionamide, cycloserine and kanamycin were performed by the proportion method on Löwenstein Jensen medium. Some level of resistance was detected among isolates from patients not previously treated with these drugs, that could be due to cross resistance with previously administered first line structural analogs. However, the studies evidenced significant association between resistance to ethionamide and cycloserine and prior treatment with these drugs. Increased resistance to all three drugs was detected within the first three months of treatment. In vitro resistance to ethionamide emerged earlier and was the most frequent followed by resistance to cycloserine and kanamycin. The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time. Simultaneous resistance to the three agents, but not to two or one drug, appeared to be a marker of treatment failure. An apparent reversion of drug resistance was observed in near 6% of patients, for whom susceptibility tests were repeated on subsequent isolates, indicating this percentage of inconsistency in reproducibility of test results. |
description |
Fil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina. |
publishDate |
2007 |
dc.date.none.fl_str_mv |
2007 |
dc.type.none.fl_str_mv |
info:ar-repo/semantics/articulo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
0025-7680 http://sgc.anlis.gob.ar/handle/123456789/144 http://www.medicinabuenosaires.com/revistas/vol67-07/3/completo/v67_3_p231_237.pdf |
identifier_str_mv |
0025-7680 |
url |
http://sgc.anlis.gob.ar/handle/123456789/144 http://www.medicinabuenosaires.com/revistas/vol67-07/3/completo/v67_3_p231_237.pdf |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Medicina (Buenos Aires) |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.coverage.none.fl_str_mv |
ARG |
dc.source.none.fl_str_mv |
Medicina (Buenos Aires) 2007; 67(3): 231-237. reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" instacron:ANLIS |
reponame_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
collection |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
instname_str |
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
instacron_str |
ANLIS |
institution |
ANLIS |
repository.name.fl_str_mv |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
repository.mail.fl_str_mv |
biblioteca@anlis.gov.ar |
_version_ |
1842344417538605056 |
score |
12.623145 |